

ASX Announcement

11 July 2025

Pharmx renews national NDSS agreement and delivers strong momentum on supplier growth – supplementary information

Pharmx Technologies (ASX:PHX) (Pharmx) – As announced earlier today, Pharmx has renewed its long-standing National Diabetes Services Scheme (NDSS) agreement.

This announcement was incorrectly marked as market sensitive. Under the agreement extension, there is no change in the terms of the existing arrangement, but it secures the contract for a further 12-month period. This includes no change to termination clauses, and no material revenue change compared with the previous financial year ending 30 June 2025.

The terms of the contract with NDSS are commercial in confidence, but the continuation of this agreement reaffirms Pharmx's commitment to national health service delivery and strengthens its position as an enabler of pharmacy operations at scale.

ENDS

This announcement has been authorised for lodgement by the Chairman.

For further information contact:

Tom Culver

Chief Executive Officer

investor.relations@pharmx.com.au



About Pharmx Technologies Ltd.

Pharmx is ANZ's leading pharmacy ordering platform, providing essential technology infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately \$20 billion in transactions annually through its robust, high-availability platform – driving efficient operations, seamless connectivity, and valuable insights across its ordering, invoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.